spravato assignment of benefits form

Once you and your doctor have decided that SPRAVATO® is right for you, enrolling into the SPRAVATO withMe Patient Support Program, including signing the patient authorization form, enables SPRAVATO withMe to help you start on your prescribed medication as soon as possible by verifying your insurance benefits, confirming coverage and sharing cost support options so that cost does not get in your way to stay adherent. You have the option to be paired with a Care Navigator,* a healthcare professional with mental health experience who can commit to help you and your caregiver:

Call SPRAVATO withMe

You can access the portal directly at SpravatoProviderPortal.com. On the landing page, you will click "create an account" and then be prompted to identify your treatment site location, contact information, and communication preferences. Upon submission, an email will be sent to the email address entered to verify your account set up. If you currently have a Janssen CarePath account for another brand, you will need to provide a new email address in order to create an account with SPRAVATO withMe. If you have questions, a SPRAVATO withMe Case Manager is available at 844-4S-WITHME (844-479-4846), Monday-Friday from 8 AM to 8 PM ET.

You can go into "My Account", scroll down the drop-down menu, click on "Staff Management" and then click on the orange button, "Add Site Staff". After you add site staff you can select their role - such as Prescriber, Nurse, Office Manager, etc., from the dropdown menu. Remember to click "SUBMIT" at the end. From this page, you can also remove staff by clicking the trash can button or by editing their information. Once removed, the user will no longer be able to access the site data.

You can add a patient by clicking the “Add a Patient” button in the top right of your dashboard. Patient Authorization forms are required to enroll your patients in the SPRAVATO withMe program and in the Savings Program - if eligible. You can print, scan and upload a signed Patient Authorization form, choose to email patients the link to the Patient Authorization form for them to sign electronically, or have them sign electronically as you are doing the enrollment in the office. Lastly, patients are also able to scan the QR code in the patient brochure to sign it remotely. A signed Patient Authorization form must be submitted to complete enrollment.

You can call the SPRAVATO withMe support line at 844-4S-WITHME, Monday – Friday, 8:00 AM – 8:00 PM.

Office/Site admin can add a provider on the portal, which will trigger an email to the provider to register on the portal. If you’ve already confirmed that you used the provider’s correct email address, ask the provider to check their spam email folder and to confirm that their email account can receive emails from the portal. You can also contact the SPRAVATO withMe support line at 844-4S-WITHME (844-479-4846), Monday - Friday, 8:00 AM - 8:00 PM

You will find a copy of the VOB in the Patient Card. Open the patient specific summary card, click on the drop-down menu "Insurance Coverage" and you will find the VOB details in the submenu.

Yes, multiple sites can be added to your profile. Upon initial account set-up when you are searching for the site, you can add more than one site. Alternatively, once the account has been created, you can click into your account profile on the top right of the dashboard and then go into site management to add or remove site associations.

Yes, you can change your communication preferences at any time. Go into "My Account", click on the drop-down menu and "Communication Preferences", where you will be able to tailor your choices.

Communication preferences are done at the individual registrant level.

If fax is chosen, the fax inputted for the site associated with the account will be used.

If the doctor is associated to multiple sites, they will see all associated sites in their site drop-down list on the portal account and the corresponding patient list within each site.

The network admin has the ability to add or remove staff as well as add or remove sites within a network (assuming the practice has multiple sites). They can edit staff or site information, approve or reject new portal users, and delegate permissions to site staff. Both the network admin and site staff have access to all patient cases that are associated with their sites.

There are two key ways to enroll your commercially insured patient into the Savings Program within the provider portal. 1. Your patient can select Optional Savings enrollment in the Program Enrollment (Patient section only) and Patient Authorization Form and, if eligible, they will be enrolled in the Savings Program by the SPRAVATO withMe Case Manager within 24 hours of submission. 2. If you need a Savings Card immediately, you can click “Enroll Patient in Savings Program” after you have completed adding the patient and answer the eligibility questions. This prompt will be available after you have added the patient, or from the Patient Summary Card. You will be able to print/download the Savings Card by going into the Patient Card, clicking on the sub-menu "Savings Program", and then clicking "download card.”

In the Patient Card, navigate to the Savings Program sub-menu. Under the Savings Program sub-menu, click the "View All Transactions" link. Here you will find a history of your transactions and can generate a report of these claims at a patient level. Claim documents that have been uploaded can be seen by clicking the individual claim documents.

You can change it by going into "My Account", then at the bottom there is an orange button, "Change Password". Passwords need to have a minimum of 10 characters, including uppercase letters, lowercase letters, numbers and special characters.

You can opt out of Prior Authorization support at any time. You can either opt out when you fill in the Program Enrollment Form by checking on the specific box or in the portal.

Color coding enhances the portal's functionality and will have the following meanings:

GREEN - Positive outcome

GREY - In Progress

YELLOW - Action Needed

RED - Denial/ Blocker

Enroll your patients in the SPRAVATO withMe program. Learn how to minimize delays in the approval process so your patients can start treatment quickly.

SPRAVATO withMe is limited to education for patients about SPRAVATO®, its administration, and/or their disease, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, or provide case management services.

Information about your patient’s insurance coverage, cost support options, and treatment support is given by service providers for SPRAVATO withMe via Janssen CarePath. The information you get does not require you or your patient to use any Janssen product. Because the information we give you comes from outside sources, SPRAVATO withMe cannot promise the information will be accurate or complete. SPRAVATO withMe cost support is not for patients in the Johnson & Johnson Patient Assistance Foundation.

• Drug Coverage
• Hypertrophic Cardiomyopathy (HCM)
• Vaccines: 2023 Year in Review
• Urothelial Carcinoma
• Women's Health
• Heart Failure
• Neonatal Care
• Type II Inflammation
• Substance Use Disorder
• Gene Therapy
• Lung Cancer
• Spinal Muscular Atrophy
• Post-Acute Care
• Liver Disease
• Pulmonary Arterial Hypertension
• Safety & Recalls
• Atrial Fibrillation
• Type I Diabetes
• Cardiovascular Diseases
• Breast Cancer
• Prescription Digital Therapeutics
• Reproductive Health
• The Improving Patient Access Podcast
• Blood Cancer
• Ulcerative Colitis
• Respiratory Conditions
• Multiple Sclerosis
• Digital Health
• Population Health
• Sleep Disorders
• Biosimilars
• Plaque Psoriasis
• Leukemia and Lymphoma
• Obstetrics-Gynecology & Women's Health
• Solid Tumors
• Autoimmune Diseases
• Dermatology
• Mental Health

J&J Warns of Risk of Respiratory Depression with Spravato

Based on reports from post-marketing experience, Spravato’s warnings and precautions section now includes the risk of respiratory depression.

Johnson & Johnson has updated the safety labeling of the antidepressant Spravato (esketamine) to include a risk of respiratory depression and respiratory arrest. These adverse events were seen with postmarketing experience.

Reina Benabou, M.D., Ph.D.

From March 2019 to February 2023, there were 40 cases of respiratory depression and two cases of respiratory arrest out of 868,000 treatment sessions, Reina Benabou, M.D., Ph.D., vice president, medical affairs, U.S. Neuroscience at J&J., said in an interview. Since its approval, Spravato has been used by 47,000 patients.

The FDA approved Spravato in March 2019 to treat adults with treatment-resistant depression, and the following year to treat adults with major depressive disorder with suicidal thoughts. In the United States, about 21 million adults have had at least one major depressive episode, with an estimated one-third — or 2.8 million — of those living with major depressive disorder who are treatment resistant.

Delivered as a nasal spray, Spravato is a chemical variant of ketamine and acts on the glutamate receptor (NMDA receptor). Taken with an antidepressant, it provides faster response than antidepressants alone.

As part of its Risk Evaluation and Mitigation Strategies (REMS), Spravato is only administered in certified centers where trained healthcare professionals are required to monitor patients for at least two hours after administration to ensure the response is well tolerated. The label update adds monitoring with pulse oximetry, which measures the oxygen in a person’s blood.

Benabous said specific details about pulse oximetry monitoring are pending with the FDA and will be included in Spravato’s REMS when that is finalized.

“The safety of our patients is our top priority,” Benabou said. “We’re working very closely with the FDA to be transparent with the data that we have. The label has been updated effective immediately and we want to raise awareness about these issues.”

Regulators did not recommend any constraints for use, but Benabou suggested that providers with patients with COPD, cardiac failure, or who are taking concomitant CNS-acting drugs will have to use discretion when prescribing Spravato.

The newly added subsection under warnings and precautions reads:

“In post marketing experience, respiratory depression was observed with the use of SPRAVATO. In addition, there were rare reports of respiratory arrest

Because of the risks of respiratory depression, patients must be monitored for changes in respiratory status by a healthcare provider for at least 2 hours (including pulse oximetry) at each treatment session, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.

Spravato is available only through a restricted program under a REMS.”

The REMS program was added to Spravato’s use when it was approved because of the risk of serious adverse outcomes resulting from sedation and dissociation associated with it, and the potential for abuse and misuse of the drug.

Research on Spravato continues. Earlier this month, J&J released data from a head-to-head phase 3 study of Spravato and quetiapine extended release (Seroquel XR) in patients with treatment-resistant depression. Patients treated with Spravato were 1.54 times as likely to reach remission after eight weeks than those treated with quetiapine and were also 1.55 times as likely to stay relapse-free up to 32 weeks. The results of this study were published   in The New England Journal Medicine .

Amneal Recalls 4 Lots of Vancomycin Because of Overfilling

The recommended maximum daily dose of Vancomycin is up to 2 grams a day. The overfilled vials could result in patients receiving up to 4 grams a day.

FDA Adds Boxed Warning to Prolia in Patients with Kidney Disease

Regulators are warning about the increased risk of very low blood calcium levels in patients with advanced chronic kidney disease.

FDA Finds No Link Between GLP-1 Drugs and Thoughts of Suicide

Regulators will continue to evaluate a possible link by reviewing meta-analysis of clinical trials across all GLP-1 products and analyzing postmarketing data in the Sentinel System.

Glass in Vials Leads to Recall of Several Hospira Products

The presence of glass can lead to serious adverse events, including inflammation of a vein and blockage of blood vessels or life-threatening blood clots.

FDA and Novo Nordisk Warn about Counterfeit Ozempic

The FDA has seized thousands of units of counterfeit Ozempic 1 mg.

FDA Issues Warning about Seizure Medications

Regulators have found that medications containing levetiracetam and clobazam have led to drug reaction with eosinophilia and systemic symptoms (DRESS), a rare and severe drug allergy.

2 Commerce Drive Cranbury, NJ 08512

609-716-7777

Psychiatric Nurse Practitioner / Director of Spravato Program

Job posting for psychiatric nurse practitioner / director of spravato program at bloom health centers.

Bloom Health Centers

Clinicians average 12 patients a day at a full caseload, and provide treatment modalities including:

• Diagnostic Evaluation
• Medication Management
• rTMS (optional)

The Director of Spravato Treatment Program is responsible for oversight of the Spravato program at their assigned location. This includes enrollment in and compliance with the risk evaluation and mitigation strategies (REMS) program, responding to patient needs during treatment, collaborating with technicians and administrative staff who support the program, and ensuring proper staffing. Hybrid model, with a minimum of two days per week in-office for the duration of Spravato treatments (offered between 8:00AM – 6:00PM).

We have several clinical practices located across Delaware, Maryland, and Virginia.

Responsibilities:

• Participation in weekly neuromodulation rounds meetings to provide clinical oversight to technicians, and monitor current patient treatment progress to ensure exceptional patient care.
• Completion of initial consultations to review clinical history and determine if Spravato is a recommended treatment course.
• Supervision of treating technicians and assistance with situations that necessitate clinician intervention, such as suicidal ideation.
• Provide clinical guidance for administration of medication, and discharge from appointment based on vitals.
• Monitor storage of medication to ensure compliance with REMS.
• Stay up-to-date with research and advancements in field.
• Assess patients following acute treatment course to determine recommendations for continued care or maintenance treatment.

Benefits Include:

• 401(k) match
• Dental insurance
• Flexible schedule
• Health insurance
• Vision insurance
• Company-provided life insurance
• PTO (including increases with years of service, holidays, and floating days)
• CEU & licensing reimbursement

Nurse Practitioner Qualifications:

• Active PMHNP license in good standing
• Active or pending CSR & DEA (depending on state)
• Microsoft Office proficient
• Understanding of DSM-V and diagnosis codes
• Organizational and time management skills
• Writing and oral communication skills
• Willingness to learn
• Experience and familiarity with Ketamine/Esketamine Treatment
• Experience with/Interest in treatment resistant depression

Medical Specialty:

Bloom Health Centers is committed to creating a diverse and inclusive workforce and provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local laws.

Job Type: Full-time

Pay: From $130,000.00 per year

• 401(k) matching
• Life insurance
• Paid time off
• Retirement plan

Medical specialties:

Standard shift:

Supplemental pay types:

• Bonus opportunities

Weekly schedule:

• Monday to Friday

Work setting:

• Hybrid work
• Multiple locations

Experience:

• EMR systems: 1 year (Preferred)

License/Certification:

• DEA (Preferred)
• Psychiatric Nurse Practitioner License (Preferred)

Ability to Relocate:

• Lutherville-Timonium, MD 21093: Relocate before starting work (Required)

Work Location: Hybrid remote in Lutherville-Timonium, MD 21093

Apply for this job

Receive alerts for other Psychiatric Nurse Practitioner / Director of Spravato Program job openings

Report this Job

Sign up to receive alerts about other jobs with skills like those required for the Psychiatric Nurse Practitioner / Director of Spravato Program .

Click the checkbox next to the jobs that you are interested in.

Clinical Supervision Skill

• Nursing Education Specialist Income Estimation: $112,204 - $137,292
• Head Nurse Income Estimation: $112,330 - $136,814

Diagnosis and Treatment Planning Skill

• Behavior Analyst Income Estimation: $63,735 - $77,866
• Certified Respiratory Therapist Income Estimation: $64,138 - $77,852

Job openings at Bloom Health Centers

Not the job you're looking for here are some other psychiatric nurse practitioner / director of spravato program jobs in the timonium, md area that may be a better fit., we don't have any other psychiatric nurse practitioner / director of spravato program jobs in the timonium, md area right now..

Psychiatric Nurse Practitioner

Long Integrated Psychiatric Services , Bel Air, MD

Medical Director/Psychiatric Nurse Practitioner

Redefining the Future Network, Inc , Baltimore, MD